Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Page 2 of 9
Sep 1, 2026The issue centers on reduced levels of stabilizing agents in catheter tips, which could increase the risk of degradation and detachment. For Boston Scientific, the halt adds a device safety problem to a year already marked by a cyberattack, restructuring and lower top-end guidance.
Aug 25, 2026RefluxStop is designed to reduce or stop acid from entering the oesophagus through an implant placed on the upper part of the stomach via keyhole surgery. The approval brings the device into the U.S. after years on the European market, but Implantica is signaling a gradual commercial rollout centered on selected centers and physician training.
Aug 24, 2026The assay detects phosphorylated Tau 217 protein, which has been linked to amyloid plaque buildup in the brain. Commercially, the clearance points to a broader diagnostic pathway that could move Alzheimer’s assessment beyond PET imaging and cerebrospinal fluid testing in selected patients.
Aug 23, 2026New long-term U.K. data gave focal therapy supporters fresh evidence, including a reported 0.1% prostate cancer mortality rate 10 years after treatment. Even so, debate persists because randomized comparisons with standard treatment remain limited and real-world use extends beyond the patients guidelines say should receive it.
Aug 21, 2026Focal therapy aims to destroy MRI-visible prostate lesions without removing or irradiating the whole gland, offering a less aggressive option than surgery or radiation for some patients with localized disease. A recent 10-year U.K. study reported 0.1% prostate cancer mortality, but the American Urological Association still says the approach should be limited to studies and prospective registries.
Aug 12, 2026Commure, a Mountain View technology company valued at $7 billion, is pitching AI tools meant to automate billing, scheduling, and clinical documentation across health care. The STAT report puts the focus less on product ambition than on the commercial methods and customer outcomes shaping adoption as AI moves deeper into provider operations.
Aug 8, 2026Although healthcare organizations routinely collect data on potential risk indicators, the inability to connect disparate pieces of information often leads to missed warning signs and reactive, rather than proactive, prevention efforts. This extended analysis explores the systemic barriers and examines pathways toward more effective workplace violence prevention in healthcare—including the critical role of emerging data technologies.
Aug 7, 2026While dentistry’s preventive paradigm has long targeted cavities and periodontal disease, new thought leadership emphasizes that how teeth, muscles, and the jaw interact over a lifetime plays a foundational role in holistic oral health. As emerging science connects bite function to chronic dental problems, the industry is re-examining what truly constitutes prevention.
Aug 6, 2026UnityPoint Health is implementing a suite of artificial intelligence (AI) solutions across its health system to streamline administrative tasks and help clinicians refocus on patient care. These measures range from real-time capacity tracking and ambient documentation to advanced AI-powered medical record review, reflecting a technology-first approach to combatting widespread burnout in healthcare.
Aug 4, 2026A persistent gap in telehealth adoption between rural and non-rural populations raises fresh questions about equitable digital health access. This new report illuminates the scale of the problem—and spotlights the challenges ahead for policymakers, providers, and technology innovators.
Jul 23, 2026Assured Health has raised $19 million for its AI agent platform, which promises to streamline and automate the provider credentialing and insurance onboarding process for health systems. The startup claims its technology can reduce timelines from months to days, potentially reshaping a major industry pain point.
Jul 21, 2026Nabla, a Paris-based AI-driven medical scribe company, has announced Brian Manning as its new CEO. The leadership change comes at a strategic moment as digital scribe vendors face mounting pressure to differentiate their technology and expand reach in the crowded clinical documentation market.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.